A total of 215 drugs for heart disease and stroke are awaiting FDA approval or are in clinical trials, according to a report from the Pharmaceutical Research and Manufacturers of America. The lineup includes 30 for heart failure, 29 for lipid disorders, 19 for stroke and 17 for hypertension.

Related Summaries